Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,547 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01252693 | International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer | completed | Phase 2 | 203 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Oct 5, 2021 | clinicaltrials |
| NCT04050215 | 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer | completed | Phase 2 | 937 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 30, 2021 |
| clinicaltrials |
| NCT01105130 | L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors | completed | Phase 2 | 140 | Wake Forest University Health SciencesOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT01535040 | Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking | completed | Phase 2 | 130 | Wake Forest University Health SciencesOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT02499497 | A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer | completed | Phase 2 | 114 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT03062254 | Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy | completed | Phase 2 | 14 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Sep 21, 2021 | clinicaltrials |
| NCT02346578 | Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy. | completed | Phase 2 | 104 | Taro Iguchi, MD, PHDOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT01804465 | Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer | completed | Phase 2 | 50 | University of California, San FranciscoOTHER | 1 | Aug 18, 2021 | clinicaltrials |
| NCT02981368 | Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer(OSPREY) | completed | Phase 2 / Phase 3 | 385 | Progenics Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 9, 2021 | clinicaltrials |
| NCT00214136 | Intensity Modulated Radiation Therapy (IMRT) Radiotherapy for Treating Prostate Pelvic Nodes | completed | Phase 2 | 30 | University of Wisconsin, MadisonOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT01505868 | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT02463799 | Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC | completed | Phase 2 | 36 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT02867020 | Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels | completed | Phase 2 | 128 | Latin American Cooperative Oncology GroupOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT00667862 | Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer | completed | Phase 2 | 35 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 21, 2021 | clinicaltrials |
| NCT01706458 | Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer | completed | Phase 2 | 18 | University of Wisconsin, MadisonOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT03361969 | Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist. | completed | Phase 2 | 63 | Pantarhei Oncology B.V.OTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT01254513 | Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients(GERICO10) | completed | Phase 2 | 66 | UNICANCEROTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT02229734 | Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2(FASTR-2) | completed | Phase 2 | 60 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT02559115 | 68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer | completed | Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT01503229 | Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 32 | University of WashingtonOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT01540071 | Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer | completed | Phase 2 | 38 | Io TherapeuticsINDUSTRY | 1 | May 14, 2021 | clinicaltrials |
| NCT00087165 | GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer | completed | Phase 2 | 22 | University Health Network, TorontoOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT01868386 | Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate(HypoFX) | completed | Phase 1 / Phase 2 | 32 | Timothy Showalter, MDOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT02987829 | Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 72 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Apr 23, 2021 | clinicaltrials |
| NCT02046837 | An Exercise Trial and Economic Analysis in Men With Prostate Cancer(ADT Ex RCT) | completed | Phase 2 | 59 | University Health Network, TorontoOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT00350051 | ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer | completed | Phase 2 | 53 | BayerINDUSTRY | 2 | Apr 8, 2021 | clinicaltrials |
| NCT00737893 | Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy(ERECT) | completed | Phase 2 | 56 | Johns Hopkins UniversityOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT02552121 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 33 | Seagen Inc.INDUSTRY | 5 | Apr 8, 2021 | clinicaltrials |
| NCT01317199 | Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer | completed | Phase 1 / Phase 2 | 143 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT02142608 | A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer | completed | Phase 1 / Phase 2 | 19 | Bracco Diagnostics, IncINDUSTRY | 2 | Mar 29, 2021 | clinicaltrials |
| NCT01468532 | Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 25, 2021 | clinicaltrials |
| NCT01615120 | Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer | completed | Phase 2 | 77 | GTxINDUSTRY | 1 | Mar 24, 2021 | clinicaltrials |
| NCT01748500 | Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 21 | University Health Network, TorontoOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT03179410 | PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer(PICK-NEPC) | completed | Phase 2 | 15 | Andrew J. Armstrong, MDOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT03263780 | High Resolution PET-MRI Before Prostate Cancer HIFU | completed | Phase 2 | 21 | Timothy J. DaskivichOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT02628041 | HDR Brachytherapy vs. LDR Brachytherapy Monotherapy in Localized Prostate Cancer(HDRvsLDR) | completed | Phase 2 | 30 | CHU de Quebec-Universite LavalOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT02004418 | A Study for Patients With Prostate Cancer to See Whether Delivering an Extra Dose of Radiation to Parts of the Body With More Cancer is Better Than Standard Treatment in Which the Same Dose of Radiation is Given Throughout the Prostate Gland(PET PRO) | completed | Phase 1 / Phase 2 | 21 | AHS Cancer Control AlbertaOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT01341652 | Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer | completed | Phase 2 | 99 | University of Wisconsin, MadisonOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT01882985 | Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients | completed | Phase 2 | 14 | University of California, IrvineOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT03418324 | Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy | completed | Phase 2 | 11 | Cedars-Sinai Medical CenterOTHER | 1 | Dec 30, 2020 | clinicaltrials |
| NCT02611882 | Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients(PSMA PET) | completed | Phase 2 | 225 | Thomas HopeOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT03348527 | A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer | completed | Phase 2 | 61 | Lidds ABINDUSTRY | 3 | Dec 21, 2020 | clinicaltrials |
| NCT02919111 | Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients(PSMA PreRP) | completed | Phase 2 / Phase 3 | 299 | University of California, San FranciscoOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT01940276 | Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer | completed | Phase 2 | 100 | Duke UniversityOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT01051570 | Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel | completed | Phase 2 | 26 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 1, 2020 | clinicaltrials |
| NCT00428714 | Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy | completed | Phase 2 | 73 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 25, 2020 | clinicaltrials |
| NCT02397408 | 11C- and 18F-Choline PET/MR Imaging for Prostate Cancer | completed | Phase 2 | 18 | University of California, San FranciscoOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT02036060 | Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.(ABIDO) | completed | Phase 2 | 119 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Nov 16, 2020 | clinicaltrials |
| NCT01576172 | Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 159 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2020 | clinicaltrials |
| NCT00466440 | A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients | completed | Phase 2 | 108 | Eli Lilly and CompanyINDUSTRY | 3 | Nov 6, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Oct 5, 2021source: clinicaltrials